This marks the second consecutive year that Americord has been recognized for its achievements. Founded in 2008 with a purpose to improve lives and change the world, the company has grown over tenfold within the last three years.
"The Inc. 5000 list stands out where it really counts," says Inc. President and Editor-In- Chief Eric Schurenberg. "It honors real achievement by a founder or a team of them. No one makes the Inc. 5000 without building something great – usually from scratch. That's one of the hardest things to do in business, as every company founder knows. But without it, free enterprise fails."
Americord continues to innovate in the stem cell banking space and hopes that more families can take advantage of the potentially lifesaving benefits of cord blood, cord tissue, and placenta tissue.
About Americord Registry ("Americord")
Americord is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. For more information, visit www.americordblood.com.
Press contact: Alysha Bullock | email@example.com | 866-503-6005
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/americord-announces-ranking-on-the-2016-inc-5000-300315991.html
SOURCE Americord Registry